Meridian Bioscience

Meridian Bioscience EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Meridian Bioscience (VIVO) as of Oct 26, 2026 is -25.75 %. In the previous year, Year-over-Year EBITDA Growth was 49.74 % — a change of -151.78% (lower).

EBITDA Growth YoY

-25.75 %

YoY

-151.78%

Last updated:

Year-over-Year EBITDA Growth of Meridian Bioscience is 2022 -25.75 % . Year-over-Year EBITDA Growth of Meridian Bioscience was 2021 49.74 % . It decreases by -151.78% lower compared to the previous year.

The Meridian Bioscience EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2015
7.06 USD
Jan 1, 2016
-4.46 USD
Jan 1, 2017
-16.42 USD
Jan 1, 2018
-0.22 USD
Jan 1, 2019
-12.98 USD
Jan 1, 2020
74.81 USD
Jan 1, 2021
49.74 USD
Jan 1, 2022
-25.75 USD
The Meridian Bioscience EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-25.75 %-151.78%
49.74 %-33.51%
74.81 %-676.53%
-12.98 %+5,712.98%
-0.22 %-98.64%
-16.42 %+268.42%
-4.46 %-163.11%
7.06 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Year-over-Year EBITDA Growth of Meridian Bioscience is -25.75 % in 2022.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Meridian Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Meridian Bioscience

All Key Metrics — Meridian Bioscience